Ieq Capital LLC Purchases 12,440 Shares of Boston Scientific Co. (NYSE:BSX)

Ieq Capital LLC boosted its position in Boston Scientific Co. (NYSE:BSXGet Rating) by 48.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 38,196 shares of the medical equipment provider’s stock after purchasing an additional 12,440 shares during the period. Ieq Capital LLC’s holdings in Boston Scientific were worth $1,480,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Newport Trust Co lifted its stake in Boston Scientific by 5,082.5% in the 2nd quarter. Newport Trust Co now owns 7,401,817 shares of the medical equipment provider’s stock worth $275,866,000 after purchasing an additional 7,258,993 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in Boston Scientific by 24.5% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 20,806,144 shares of the medical equipment provider’s stock worth $775,455,000 after purchasing an additional 4,088,589 shares during the period. Lazard Asset Management LLC raised its position in Boston Scientific by 23.6% in the 2nd quarter. Lazard Asset Management LLC now owns 12,653,052 shares of the medical equipment provider’s stock worth $471,578,000 after purchasing an additional 2,416,974 shares during the period. Arrowstreet Capital Limited Partnership raised its position in Boston Scientific by 65.9% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 5,430,814 shares of the medical equipment provider’s stock worth $240,531,000 after purchasing an additional 2,157,849 shares during the period. Finally, Artisan Partners Limited Partnership raised its position in Boston Scientific by 10.6% in the 2nd quarter. Artisan Partners Limited Partnership now owns 19,323,700 shares of the medical equipment provider’s stock worth $720,194,000 after purchasing an additional 1,849,604 shares during the period. 90.23% of the stock is owned by institutional investors.

Boston Scientific Stock Down 0.0 %

Shares of BSX stock opened at $45.84 on Wednesday. Boston Scientific Co. has a 12 month low of $34.98 and a 12 month high of $47.95. The stock has a market cap of $65.66 billion, a P/E ratio of 109.15, a P/E/G ratio of 2.30 and a beta of 0.83. The company has a current ratio of 1.45, a quick ratio of 0.95 and a debt-to-equity ratio of 0.49. The company has a 50 day simple moving average of $45.56 and a two-hundred day simple moving average of $42.39.

Boston Scientific (NYSE:BSXGet Rating) last announced its earnings results on Wednesday, October 26th. The medical equipment provider reported $0.43 EPS for the quarter, missing analysts’ consensus estimates of $0.44 by ($0.01). Boston Scientific had a net margin of 5.19% and a return on equity of 14.55%. The business had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. During the same period in the prior year, the company posted $0.41 earnings per share. The firm’s quarterly revenue was up 8.1% on a year-over-year basis. On average, research analysts expect that Boston Scientific Co. will post 1.73 earnings per share for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 125,827 shares of the company’s stock in a transaction that occurred on Monday, November 7th. The shares were sold at an average price of $41.97, for a total transaction of $5,280,959.19. Following the completion of the sale, the chief executive officer now directly owns 1,767,665 shares of the company’s stock, valued at $74,188,900.05. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Boston Scientific news, CEO Michael F. Mahoney sold 125,827 shares of the company’s stock in a transaction that occurred on Monday, November 7th. The shares were sold at an average price of $41.97, for a total value of $5,280,959.19. Following the completion of the transaction, the chief executive officer now directly owns 1,767,665 shares in the company, valued at $74,188,900.05. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Jeffrey B. Mirviss sold 11,080 shares of the company’s stock in a transaction that occurred on Monday, December 12th. The stock was sold at an average price of $46.75, for a total transaction of $517,990.00. Following the completion of the transaction, the executive vice president now owns 88,479 shares of the company’s stock, valued at $4,136,393.25. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 220,265 shares of company stock valued at $9,561,634. Insiders own 0.66% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Mizuho assumed coverage on shares of Boston Scientific in a research report on Thursday, December 22nd. They issued a “neutral” rating and a $52.00 target price on the stock. TheStreet cut shares of Boston Scientific from a “b-” rating to a “c” rating in a research report on Monday, November 28th. Citigroup started coverage on shares of Boston Scientific in a research report on Tuesday, December 20th. They issued a “buy” rating and a $54.00 price objective on the stock. Raymond James boosted their price objective on shares of Boston Scientific from $48.00 to $54.00 in a research report on Thursday, December 8th. Finally, Canaccord Genuity Group boosted their price objective on shares of Boston Scientific from $45.00 to $48.00 and gave the company a “buy” rating in a research report on Friday, October 28th. Three investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average price target of $50.00.

Boston Scientific Company Profile

(Get Rating)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.

Featured Stories

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSXGet Rating).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.